Literature DB >> 7829091

Assignment of the human MAD and MXI1 genes to chromosomes 2p12-p13 and 10q24-q25.

D N Shapiro1, V Valentine, L Eagle, X Yin, S W Morris, E V Prochownik.   

Abstract

MAD and MXI1, two recently described members of the basic helix-loop-helix (bHLH) gene family, encode proteins that dimerize with and modulate the DNA binding of max. In turn, mad-max or mxi1-max heterodimers or max homodimers can compete for DNA binding sites with dimers formed between max and myc oncoproteins and antagonize the transcriptional activities of this latter class of proteins. Using a combination of somatic cell mapping and fluorescence in situ hybridization techniques, we have determined the chromosomal locations of the MAD and MXI1 genes. The MAD gene maps to chromosome 2p12-p13, a region involved in translocations and deletions in acute and chronic lymphocytic leukemias as well as non-lymphocytic leukemias and Hodgkin disease. The MXI1 gene localizes to chromosome 10q24-q25, a region involved in translocations and deletions in acute and chronic lymphocytic leukemias and prostatic carcinomas. The availability of genomic clones of MAD and MXI1 will permit an assessment of their involvement in these diseases at the molecular level.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7829091     DOI: 10.1006/geno.1994.1496

Source DB:  PubMed          Journal:  Genomics        ISSN: 0888-7543            Impact factor:   5.736


  10 in total

1.  Mad1 function is regulated through elements within the carboxy terminus.

Authors:  G Barrera-Hernandez; C M Cultraro; S Pianetti; S Segal
Journal:  Mol Cell Biol       Date:  2000-06       Impact factor: 4.272

2.  Induction of Mxi1-SR alpha by FOXO3a contributes to repression of Myc-dependent gene expression.

Authors:  Oona Delpuech; Beatrice Griffiths; Philip East; Abdelkader Essafi; Eric W-F Lam; Boudewijn Burgering; Julian Downward; Almut Schulze
Journal:  Mol Cell Biol       Date:  2007-04-23       Impact factor: 4.272

Review 3.  c-Myc target genes involved in cell growth, apoptosis, and metabolism.

Authors:  C V Dang
Journal:  Mol Cell Biol       Date:  1999-01       Impact factor: 4.272

4.  Function of the c-Myc antagonist Mad1 during a molecular switch from proliferation to differentiation.

Authors:  C M Cultraro; T Bino; S Segal
Journal:  Mol Cell Biol       Date:  1997-05       Impact factor: 4.272

Review 5.  Normal and Neoplastic Growth Suppression by the Extended Myc Network.

Authors:  Edward V Prochownik; Huabo Wang
Journal:  Cells       Date:  2022-02-21       Impact factor: 6.600

6.  Development of a Risk Score Model for Osteosarcoma Based on DNA Methylation-Driven Differentially Expressed Genes.

Authors:  Yuxiang Kang; Guowang Li; Guohua Wang; Zhenxin Huo; Xiangling Feng; Lilong Du; Yongjin Li; Qiang Yang; Xinlong Ma; Bingbing Yu; Baoshan Xu
Journal:  J Oncol       Date:  2022-05-13       Impact factor: 4.501

7.  Mxi1-0, an alternatively transcribed Mxi1 isoform, is overexpressed in glioblastomas.

Authors:  Lars D Engstrom; Andrew S Youkilis; Judith L Gorelick; Datong Zheng; Valerie Ackley; Christy A Petroff; Linda Q Benson; Melissa R Coon; Xiaoxiang Zhu; Samir M Hanash; Daniel S Wechsler
Journal:  Neoplasia       Date:  2004 Sep-Oct       Impact factor: 5.715

8.  Mxi1 mutations in human neurofibrosarcomas.

Authors:  X J Li; D Y Wang; Y Zhu; R J Guo; X D Wang; K Lubomir; K Mukai; H Sasaki; H Yoshida; T Oka; R Machinami; K Shinmura; M Tanaka; H Sugimura
Journal:  Jpn J Cancer Res       Date:  1999-07

9.  The expression of HtrA2 and its diagnostic value in patients with hepatocellular carcinoma.

Authors:  Honggang Wang; Fuguo Jiang; Furong Hao; Ruixue Ju
Journal:  Medicine (Baltimore)       Date:  2018-04       Impact factor: 1.889

10.  mRNA microarray profiling identifies a novel circulating HTRA2 for detection of gastric cancer.

Authors:  Liangliang Wu; Xiao Li; Xin Chen; Fan Wu; Guangshun Sun; Ye Cheng; Weiwei Tang; Wenling Zhang; Chengyu Lv
Journal:  J Clin Lab Anal       Date:  2021-10-28       Impact factor: 2.352

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.